Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Albireo Pharma Inc
(NQ:
ALBO
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Mar 2, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Albireo Pharma Inc
< Previous
1
2
3
Next >
Albireo Pharma: Q1 Earnings Insights
May 16, 2022
Albireo Pharma (NASDAQ:ALBO) reported its Q1 earnings results on Monday, May 16, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Albireo Pharma missed estimated...
Via
Benzinga
Earnings Scheduled For May 16, 2022
May 16, 2022
Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.
Via
Benzinga
Albireo Pharma's Earnings Outlook
May 13, 2022
Albireo Pharma (NASDAQ:ALBO) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement. Analysts estimate that Albireo Pharma...
Via
Benzinga
Albireo Pharma Earnings Perspective: Return On Capital Employed
March 03, 2022
Benzinga Pro data, Albireo Pharma (NASDAQ:ALBO) reported Q4 sales of $32.52 million. Earnings fell to a loss of $10.96 million, resulting in a 119.2% decrease from last quarter....
Via
Benzinga
Recap: Albireo Pharma Q4 Earnings
March 01, 2022
Albireo Pharma (NASDAQ:ALBO) reported its Q4 earnings results on Tuesday, March 1, 2022 at 08:30 AM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
Earnings Scheduled For March 1, 2022
March 01, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...
Via
Benzinga
5 Beaten Down Biotech Stocks That Could Bounce Big In 2022
December 27, 2021
Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout...
Via
Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
May 01, 2021
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...
Via
Benzinga
Exposures
Product Safety
80 Biggest Movers From Yesterday
March 02, 2022
Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) jumped 78.5% to close at $0.6066 on Tuesday after jumping 36% on Monday. CTI BioPharma Corp. (NASDAQ: CTIC) surged 63...
Via
Benzinga
Albireo Pharma, inc (ALBO) Q3 2021 Earnings Call Transcript
November 04, 2021
ALBO earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Albireo Pharma Sells Bylvay-Associated PRV For $105M
September 07, 2021
Albireo Pharma Inc (NASDAQ: ALBO) has agreed to sell its Priority Review Voucher (PRV) for $105 million. The FDA granted the PRV for Bylvay to treat pruritus...
Via
Benzinga
Exposures
Product Safety
Looking into Albireo Pharma's Return on Capital Employed
August 27, 2021
After pulling data from Benzinga Pro it seems like during Q2, Albireo Pharma (NASDAQ:ALBO) posted sales of $2.43 million. Earnings were up 16.96%, but Albireo Pharma still...
Via
Benzinga
Albireo Pharma, inc (ALBO) Q2 2021 Earnings Call Transcript
August 07, 2021
ALBO earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates
August 02, 2021
The month of July was disappointing from the perspective of Food and Drug Administration decisions, as the agency handed down mostly negative verdi...
Via
Benzinga
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs, And More
July 25, 2021
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefited from the optimism that was set in motion by the solid start to the pharma reporting...
Via
Talk Markets
Exposures
Product Safety
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
July 25, 2021
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start...
Via
Benzinga
Exposures
Product Safety
Albireo's Rare Liver Disease Drug Bylvay Scores Back To Back Approvals In Europe, US
July 21, 2021
Just a day after European approval, Albireo Pharma Inc (NASDAQ: ALBO) has received FDA approval for Bylvay (odevixibat), the first drug approved to treat...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
July 20, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated...
Via
Benzinga
Albireo's Bylvay Scores European Nod For Rare Pediatric Liver Disease
July 19, 2021
The European Commission (EC) has approved Albireo Pharma Inc's (NASDAQ: ALBO) Bylvay (odevixibat) for all subtypes of progressive familial intrahepatic...
Via
Benzinga
The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs
July 18, 2021
Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week stoked rate hike fears,...
Via
Talk Markets
Exposures
Product Safety
The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs
July 18, 2021
Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week...
Via
Benzinga
Exposures
Product Safety
Attention Biotech Investors: Mark Your Calendar For July PDUFA Dates
July 01, 2021
June was a month of plenty and also turned out to be a fruitful one from the perspective of Food and Drug Administration approvals. Regulatory reviews mostly produced positive...
Via
Benzinga
Albireo's Bylvay Shows Further Evidence Of Sustained, Durable Effect In Pediatric Liver Disease Study
June 21, 2021
Albireo Pharma Inc (NASDAQ: ALBO) has announced pooled analysis from Phase 3 PEDFIC studies with Bylvay (odevixibat) and advancement in the characterization of...
Via
Benzinga
Albireo's Bylvay Wins Positive Opinion from EMA For Rare Pediatric Liver Disease
May 21, 2021
European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization to Albireo Pharma Inc...
Via
Benzinga
Albireo Pharma, Inc. (ALBO) Q1 2021 Earnings Call Transcript
May 07, 2021
ALBO earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
May 06, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.